MX2018007281A - Composiciones farmaceuticas que comprenden derivado de fenilaminopirimidina. - Google Patents

Composiciones farmaceuticas que comprenden derivado de fenilaminopirimidina.

Info

Publication number
MX2018007281A
MX2018007281A MX2018007281A MX2018007281A MX2018007281A MX 2018007281 A MX2018007281 A MX 2018007281A MX 2018007281 A MX2018007281 A MX 2018007281A MX 2018007281 A MX2018007281 A MX 2018007281A MX 2018007281 A MX2018007281 A MX 2018007281A
Authority
MX
Mexico
Prior art keywords
pharmaceutical compositions
phenylaminopyrimidine derivative
compositions
nrc
polymorphs
Prior art date
Application number
MX2018007281A
Other languages
English (en)
Inventor
Maheswari Parvataneni Durga
Satya Bhujanga Rao Adibhatla Kali
Chowdary Nannapaneni Venkaiah
Mohanty Mitrabhanu
Satyanarayana Appadwedula Venkata
Original Assignee
Natco Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Natco Pharma Ltd filed Critical Natco Pharma Ltd
Publication of MX2018007281A publication Critical patent/MX2018007281A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a una formulación farmacéutica que contiene una cantidad efectiva de NRC-AN-019 que incluye sus sales farmacéuticamente aceptables y polimorfos de los mismos, dispersando en un sistema polimérico en un estado final de subdivisión para mejorar la biodisponibilidad oral. También se refiere a procesos para la preparación de tales composiciones y usar estas composiciones para el tratamiento de Leucemia Mieloide Crónica y otros tumores tales como cáncer de cabeza y cuello, cáncer de próstata y similares.
MX2018007281A 2015-12-18 2016-01-30 Composiciones farmaceuticas que comprenden derivado de fenilaminopirimidina. MX2018007281A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN6951CH2015 2015-12-18
PCT/IN2016/050035 WO2017103941A1 (en) 2015-12-18 2016-01-30 Pharmaceutical compositions comprising phenylaminopyrimidine derivative

Publications (1)

Publication Number Publication Date
MX2018007281A true MX2018007281A (es) 2018-11-29

Family

ID=59055898

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018007281A MX2018007281A (es) 2015-12-18 2016-01-30 Composiciones farmaceuticas que comprenden derivado de fenilaminopirimidina.

Country Status (32)

Country Link
US (1) US10383872B2 (es)
EP (1) EP3389633B1 (es)
JP (2) JP6896738B2 (es)
KR (1) KR20180102584A (es)
CN (1) CN108495620B (es)
AU (1) AU2016373574B2 (es)
BR (1) BR112018012458A2 (es)
CA (1) CA3008634A1 (es)
CL (1) CL2018001590A1 (es)
CO (1) CO2018007112A2 (es)
CY (1) CY1124580T1 (es)
DK (1) DK3389633T3 (es)
EA (1) EA036513B1 (es)
ES (1) ES2881883T3 (es)
GB (1) GB2564262A (es)
GE (1) GEP20207176B (es)
HK (1) HK1254573A1 (es)
HR (1) HRP20211590T1 (es)
HU (1) HUE056269T2 (es)
IL (1) IL260085B (es)
LT (1) LT3389633T (es)
MA (1) MA44079B1 (es)
MX (1) MX2018007281A (es)
PH (1) PH12018501292A1 (es)
PL (1) PL3389633T3 (es)
PT (1) PT3389633T (es)
RS (1) RS62422B1 (es)
SG (1) SG11201805142RA (es)
SI (1) SI3389633T1 (es)
UA (1) UA122592C2 (es)
WO (1) WO2017103941A1 (es)
ZA (1) ZA201804203B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12084472B2 (en) 2015-12-18 2024-09-10 Ardelyx, Inc. Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists
TW202246215A (zh) 2015-12-18 2022-12-01 美商亞德利克斯公司 作為非全身ｔｇｒ５促效劑之經取代之４－苯基吡啶化合物
CZ2017821A3 (cs) * 2017-12-20 2019-07-03 Zentiva, K.S. Léková forma obsahující krystalický nilotinib
CN112118830B (zh) * 2018-05-14 2023-11-10 比利时胶囊公司 高活性剂载量的固体剂型
JP7368548B2 (ja) * 2021-07-02 2023-10-24 昊運股▲フン▼有限公司 薬学的組成物及びその使用
CN115583634B (zh) * 2022-09-21 2023-06-06 广东工业大学 一种碳氮聚合物材料的制备方法及应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002241268A (ja) * 2000-12-11 2002-08-28 Takeda Chem Ind Ltd 水溶解性が改善された医薬組成物
UA94570C2 (en) 2004-09-09 2011-05-25 Натко Фарма Лимитед Phenylaminopyrimidine derivatives as inhibitors of bcr-abl kinase
US8067422B2 (en) 2008-03-04 2011-11-29 Natco Pharma Limited Crystal form of phenylamino pyrimidine derivatives
WO2012002547A1 (ja) * 2010-07-02 2012-01-05 富士化学工業株式会社 ボセンタン固体分散体
GB2488788B (en) * 2011-03-07 2013-07-10 Natco Pharma Ltd Oral formulation of phenylaminopyrymidine compound with enhanced bioavailability and pharmacological response
CN102836159B (zh) * 2011-06-24 2014-12-10 南京圣和药业股份有限公司 达沙替尼分散体及其制备方法和其在片剂中的应用
WO2015095659A2 (en) * 2013-12-20 2015-06-25 Phosphorex, Inc. Indirubin solid dispersion composition

Also Published As

Publication number Publication date
MA44079A (fr) 2021-04-21
ZA201804203B (en) 2020-08-26
US20190015412A1 (en) 2019-01-17
GEP20207176B (en) 2020-11-10
IL260085A (en) 2018-07-31
AU2016373574A1 (en) 2018-07-12
CN108495620A (zh) 2018-09-04
MA44079B1 (fr) 2021-10-29
PH12018501292A1 (en) 2019-02-04
HK1254573A1 (zh) 2019-07-19
CN108495620B (zh) 2021-09-03
HRP20211590T1 (hr) 2022-01-07
EP3389633A4 (en) 2019-08-07
JP2018538325A (ja) 2018-12-27
JP6896738B2 (ja) 2021-06-30
IL260085B (en) 2021-09-30
AU2016373574B2 (en) 2021-10-14
EA036513B1 (ru) 2020-11-18
BR112018012458A2 (pt) 2018-12-18
CA3008634A1 (en) 2017-06-22
EP3389633B1 (en) 2021-07-14
UA122592C2 (uk) 2020-12-10
DK3389633T3 (da) 2021-08-30
GB201811142D0 (en) 2018-08-22
GB2564262A (en) 2019-01-09
LT3389633T (lt) 2021-09-10
WO2017103941A1 (en) 2017-06-22
EA201891443A1 (ru) 2019-01-31
JP2021059551A (ja) 2021-04-15
RS62422B1 (sr) 2021-10-29
CL2018001590A1 (es) 2018-11-30
CO2018007112A2 (es) 2018-07-19
SG11201805142RA (en) 2018-07-30
ES2881883T3 (es) 2021-11-30
PT3389633T (pt) 2021-08-05
HUE056269T2 (hu) 2022-02-28
PL3389633T3 (pl) 2021-12-13
SI3389633T1 (sl) 2021-11-30
KR20180102584A (ko) 2018-09-17
CY1124580T1 (el) 2022-07-22
GEAP201614833A (es) 2020-06-25
EP3389633A1 (en) 2018-10-24
US10383872B2 (en) 2019-08-20

Similar Documents

Publication Publication Date Title
PH12018501292A1 (en) Pharmaceutical compositions comprising phenylaminopyridine derviative
PH12019500830A1 (en) 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer
PH12017500367A1 (en) Compounds that inhibit mcl-1 protein
TN2017000511A1 (en) New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them.
MA39986A (fr) Dérivés de purine en tant qu'inhibiteurs de cd73 pour le traitement du cancer
PH12018500605A1 (en) New pyrrolo[2,3-d]pyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them
TW201613593A (en) Molecules for administration to ROS1 mutant cancer cells
BR112012027743A2 (pt) ciclopropil dicarboxamidas e análogos exibindo atividades anticâncer e antiproliferativas
PH12019501896A1 (en) Therapeutic dendrimers
HRP20191265T8 (hr) Supstituirani 2-tiokso-imidazolidin-4-oni i njihovi spiro analozi, aktivni anti-kancerogeni sastojak, farmaceutska kompozicija, medicinski preparat, metoda za liječenje raka prostate
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
MX2016003522A (es) Derivados de quinazolinas y su uso como inhibidores de la adn metiltransferasa.
MX2016010272A (es) Derivado de indolona sustituido por pirrol, metodo de preparacion del mismo, composicion que comprende el mismo y uso del mismo.
MX2016009621A (es) Derivados de fur0-3-carboxamida y metodos de uso.
EA033423B1 (ru) Циклопропанбензофуранилпиридопиразиндионы
MX2018004696A (es) Analogos de epotilona, metodos de sintesis, metodos de tratamiento y conjugados con farmacos de los mismos.
MX2017002544A (es) Derivados de isoquinolinona utiles en el tratamiento contra el cancer.
WO2016112304A8 (en) Furoquinolinediones as inhibitors of tdp2
MX2015015290A (es) Compuestos furanona como inhibidores de quinasa.
MX2015017124A (es) Combinacion de ro5503781, capecitabina y oxaliplatino para la terapia para el cancer.
IN2013MU03838A (es)

Legal Events

Date Code Title Description
FG Grant or registration